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From the Departments Cyclosporine A (GA) is a neutral lipophilic compound that was 
of Dermatology and first isolated in the 1970s from the fungal species Tolypocladium 
Internal Medicine, inflatwri gams. CsA is a cyclic polypeptide that consists of 11 amino 
University of Michi- acids and that has a molecular weight of 1202 daltons.’ It was found 
yan Medical Center, to have potent immunosuppressive properties and was initially used 
Ann Arbor, Michigan, in the late 1970s to prevent organ rejection following transplantation. 
CsA first became available for general use in North America in 1983 
and is now perhaps the most widely used drug to prevent graft 
rejection in transplantation medicine. The spectrum of conditions for 
which CsA is now being used has broadened, with recent reports 
of its benefit in several autoimmune and cutaneous diseases. 
Pharmacology 
The oral route is the most common form in which CsA is presently 
prescribed in dermatology. The intramuscular route may result in 
poor absorption with subsequent wide variations in serum CsA levels,2 
and the intravenous mode is rarely used for the treatment of cutaneous 
diseases. The topical and intralesional routes have been reported to 
be of some efficacy in selected disorder+‘” and are not discussed 
in this article. CsA is absorbed from the gastrointestinal tract and 
metabolized by the liver. There is subsequent enterohepatic 
circulation of CsA. The bioavailability of oral, absorbed drug is 
approximately one-third,‘” with peak levels occurring about 3 hours 
following ingestion. The average half-life is 19 hours (range, 8-24).i5 
After CsA has been taken orally, there are wide variations in CsA 
pharmacokinetics among patients, resulting in a range of CsA trough 
levels for the same ingested CsA dose. 
The CsA dosage does not correlate with peak CsA levels, trough 
CsA levels at 24 hours, or peak minus trough levels.‘” Although the 
actual peak level may not correlate with the incidence of adverse 
reaction, a low peak-to-trough ratio of CsA levels may be associated 
with an accumulation of CsA, which may subsequently result in more 
severe side effects.lT 
Supported in part by 
the Babcock Endou- 
ment Fu,nd. 
At present, suggested guidelines for the short-term use of oral CsA 
in dermatology are as follows: oral CsA dose should be under 5 mg/ 
kg/day: serum creatinine levels should not become 50% greater than 
the baseline value while the patient is on CsA; and trough blood CsA 
levels, high-performance liquid chromatography (HPLC) or 
monoclonal radioimmunoassay (RIA), must be kept under 250 ng/ 
ml (or polyclonal RIA under 500 ng/ml). 
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Some common drug interactions with CsA 
are given in Table 10-1.18-20 Certain drugs 
induce hepatic cytochrome P450, thereby 
decreasing CsA levels. Other drugs inhibit 
cytochrome r450 and other hepatic enzymes, 
resulting in elevated CsA blood levels. Because 
CsA can cause renal dysfunction, drugs that 
may cause synergistic nephrotoxicity should 
be used with caution. 
TABLE 10-l. Common Drug Interactions with 
Cyclosporine 
Dermatologic Applications 
In CsA-responsive dermatoses, CsA may 
have an effect by inhibiting T-cell activation 
and lymphokine production. At present the 
cutaneous condition for which CsA has been 
most widely used is psoriasis. Mueller and 
Herrman21 treated four patients with psoriasis 
and psoriatic arthritis with oral CsA (300-400 
mg/ day). All patients responded within 1 week 
but worsened upon discontinuation of drug. 
The beneficial results of CsA in psoriasis and 
psoriatic arthritis were confirmed by several 
open studies and two double-blind studies 
using oral CsA (1-14 mg/kg/day).2’-3’ The 
details of these studies are given in Table lo- 
2. Both the rate of response of psoriasisvulgaris 
and the incidence of side effects appear to be 
dose dependent. At the moment, the authors 
are carrying out a double-blind, placebo- 
controlled study to determine the most suitable 




Induced hepatic cytochrome Pdso enzymes and 






sulfadimidine plus trimethoprim-only when 
given intravenously 
Inhibit metabolism of hepatic cytochrome PdsO 














nonsteroidal anti-inflammatory drugs 
melphalan 
amphotericin B 
trimethoprim plus sulfamethoxazole-oral 
cotrimoxazole-oral 
Use of oral CsA has also been reported for ment in both ocular and nonocular symptoms 
various other cutaneous diseases. Pemphigus (Table lo-2).58@ Most patients with mycosis 
(vulgaris, foliaceous, and erythematosus fungoides who have been treated with CsA 
forms) and bullous pemphigoid have generally have had advanced disease. Generally, there 
responded to CsA alone or to a combination has been some initial improvement in 
of CsA and corticosteroids. (Table lo-2).33-45 erythema and pruritus, but the long-term 
Dermatomyositis and polymyositis have response has been poor (Table lo-2).63-68 In open 
responded to CsA alone or in combination with studies, atopic dermatitis patients have 
corticosteroids, with improvement usually demonstrated clinical responses to CsA,‘j9~70 but 
occurring within the first few weeks of therapy flares can clearly occur in patients who have 
(Table lo-2).46-62 CsA alone or in conjunction previously improved using the drug. One 
with prednisone or other immunosuppressive patient with ichthyosis vulgaris improved with 
agents has been used for the therapy of lupus CsA therapy,71 but we found it to be ineffective 
erythematosus. CsA may have a role as a in five patients with lamellar ichthyosis.72 
corticosteroid-sparing agent, but it will Alopecia areata appears to be a CsA responsive 
probably not be effective monotherapy in this disorder,73-75 and further double-blind studies 
condition.5s-s7 In open studies, Behcet’s disease are needed to confirm its efficacy. Except for 
appears to be CsA responsive, with improve- one case of rapidly progressing scleroderma,l’j 




TABLE 10-2. Summary of Studies of Cyclosporine A 




patients Therapy Regimen Outcome 
Reported 
Side Effects 







Harper et al ,23 
1984, U.K 
Van Hoof et al.,24 
1985, Netherlands 
Ellis et al.,25 1986, 
U.S.A. (double- 
blind) 








Bencinl et al ,3’ 
1986 
Wentzell et al ,32 
1987, U.S A. 
Picascla et al.,33 
1987, Netherlands 
PA and PV 
(4) 
CsA 300-900 mg/day 
(oral) 
PA and PV 
(4) 
PV and PA 
PV (1) 
CsA 750-900 mg/day 
initially (oral). After 2 
weeks, CsA 200-400 mg/ 
day 
CsA (5 mg/kg/day; oral) 
After 4 weeks, CsA raised 
to 6 mg/kg/day 
Renal transplant patlent on 
prednisolone and CsA 
PV (21) CsA 14 mg/kg/day (oral; 
mean dosage) for 4 weeks 
PV (5) CsA 5 mg/kg/day (oral. 
mean dosage) for 4 weeks 





CsA started with 1 mg/kg/ 
day. Increased every 2 
weeks by 1 mg/kg/day to a 
maximum of 5 mg if 
response not observed. 
Clearance noted at mean 
dose 3.3 mg/kg/day 
Eight subjects, initial CsA- 
2 mg/kg/day; two subjects, 
Initial CsA-3 mg/kg/day 
According to clinical 
response, CsA maximum 4 
mg/kg/day 
PV (7) CsA l-3 mg/kg/day (oral) 













erythrodermic(oral) mltially, then CsA 
(2) reduced 
CsA 5-15 mg/kg/day (oral) 
over mean of 4 weeks 
(range 2.5-8 weeks). 
CsA 7.5-8.5 mg/kg/day 
Improvement in PA and 
psoriasis. 
improvement in psoriasis. 
Improvement of PA in two 
patients after 7-9 weeks of 
therapy. 
Psoriasis-clear at 75 
days. PA improvement at 6 
weeks 
Almost complete clearing 
of psoriasis within days of 
starting GSA. 
Total clearing or moderate 







two patients after 23 
weeks. Pustular 
psoriasis-no response 
By 8 weeks: Total 
clearance-5 subjects. Up 
to 85% clearance-5 
subjects. Therapeutic dose 
of CsA 3 mg/kg/day. 12- 
week study 
SIX of seven patients 
cleared. One dropout- 




Markedly improved -10 
patients. Dropout-one 
patient 
All four patients 
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TABLE 10-2. (Continued) 




patients Therapy Regimen Outcome 
Reported 
Side Effects 
Meinardi et al.,s4 
1987, Netherlands 
van Joost et al.,35 
1988, Netherlands 
(double-blind) 
Zachriae et al.,36 
1987, Denmark 
















PA, PV (6) 
CsA 12 mgfkglday (oral) 
initially 
CsA mean dose 5.5 mg/kg/ 
day (oral) 
CsA (14-5 mg/kg/day) 
(oral) 14 mg/kg/day. 
Response to disease was 
dose dependent 
CsA 6 mg/kg/day (oral) for 
8 weeks 





elevation of serum 
creatinine. CsA decreased 
to 5 mg/kg/day-new 
psoriatic lesions. Steroids 
added. 4 months later 
creatinine normal. CsA 
raised to 9 mg/kg/day. 
Steroids discontinued. 
Remission 9 months later. 
Patient on CsA 4 mglkgl 
day. No recurrence 
Improvement-greater 
than 75% PASI score in 15 
of 18 patients on active 
drug within 4 weeks 
Clearing within 1 week on 
CsA 
Clearing of psoriasis in all 
patients. Improvement in 
certain parameters of PA. 
Worsening of disease 

















Pemphigus Vulgaris (PV) and Bullous Pemphigoid (BP) 
Thivolet et al.,38 PV (2) CsA 6 mg/kg/ciay (oral) 
1985, France plus prednisone 1 mg/kg/ 
day 
BP (1) CsA 6 mg/kg/day (oral) 
plus prednisone 
PV (1) CsA 6 mg/kg/day (oral) 




No response to steroids. 
Started CsA 6-8 mg/kg/ 
day (oral) 
CsA 6-8 mg/kg/day (oral) 
PV (4) Patients steroid resistant 
Healing of lesions after lo- None 
15 days of CsA 
Lesions healed over 3 
weeks 




Two responded; two None 
failures for whom 
prednisone 0.5 mglkgfday 
added with subsequent 
response in one patient 
Responded to CsA None 
One responded. Three None 
nonresponders, in whom 
prednisone 0.5 mg/kg/day 
added, with successful 
response 
Responded to CsA None 
Clinics 
in 
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TABLE 10-2. (Continued) 




patients Therapy Regimen Outcome 
Reported 
Side Effects 





















CsA 3 5-6 5 mg/kg/day 
(oral) combined with 
Prednisone (7.5510 mg 
every 2 days) 
CsA (approx 150 mg/day. 
oral) with prednisone (8- 
15 mgiday) 
Unresponsive to 
azathioprine 50 mg tld and 
prednisone (100 mg/day) 
CsA 250 mg/day (oral) 
added 
CsA (approx 10 mg/kg/ 
day; oral) 
CsA 6-8 mg/kg/day (oral) 
prednisone 0 5-l mg/kg/ 
day added in some cases 
Responded to CsA None 
Good response over 2 
months 
Hypertnchosis 
Good response. After 3 
months, CsA reduced to 
150 mg/day, later reduced 




One patlent responded to Gingivitis, 
CsA alone. Five patients hypertrichosis, 
responded to combination hypertension, renal and 
therapy of CsA hepatic dysfunction 
prednisone Three pattents 
no response to CsA alone 
Two of these responded 
when prednisone added 
Dermatomyositis (DM) and Polymyooilis (PM) 
Zabel et al.,46 1984, DM (1) 
W. Germany 
CsA 3 mg/kg/day (IV) 
Bendtzen et al ,4r 
1984, Denmark 





The et al ,50 1985, 
Netherlands 







CsA 7 5-10 mg/kg/day Improvement within 1 
(oral) week 
Patient required 
prednlsolone 100 mg/day 
for control. Resulting side 
effects were severe. 
Started on CsA 10 mg/kg, 
day (oral) 
Withtn a few weeks of 
starting CsA. able to 
reduce steroids 
Lack of response to 
prednisone 75 mg/day and 
azathioprine 150 mg/day 
Started on CsA 7 5 mg/kg, 
day 
CsA 10 mg/kg/day (oral) 
After 4 weeks, CsA 
reduced to 5 mg/kg/day 
Maintenance dose: 5 mg/ 
kg/day (at 1 yr) 
Improvement wlthin 
weeks. Prednisone 
reduced 80 mg to 12 5 mg/ 
day while on CsA 
Improvement wlthin 2 
weeks Two months after 
start of CsA. muscle 
enzymes normal. After 1 
yr of therapy complete 
remission 
Patlent 1 CsA 7 5 mg/kg/ 
day (oral) with 
prednisolone 10 mg and 60 
mg on alternate days 
Patlent 2. CsA 5 mg/kg/ 
day (oral) plus 
prednlsolone 10 mg/kg/ 
dav 
No response in 7 weeks 
Unresponsive to steroids 
and CsA (3 months 
therapy) 
WIthIn a few days-cltnical 
Improvement, decrease of 
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TABLE 10-2. (Continued) 




patients Therapy Regimen Outcome 
Reported 
Side Effects 
Girardin et al.,52 
1988 
DM (1) CsA 5 mg/kg/day (oral), Good response. CsA 
plus prednisone 0.1 mg/ adjusted to keep CsA 
kg/day. After 8 months of whole blood (level approx 
CsA. patient still in 300 ng/ml) 
remission 
Behget’s Disease and lnntraocular Inflammatory Disease 
Nussenblatt et al.,58 Bilateral, CsA 10 mg/kg/day (oral) 
1983. U.S.A. posterior Behqet’s disease. 
uveitis of Improvement of nonocular 
non- symptoms also 
infectious 
origin (8) 
French-Constant et Behqet’s CsA 10 mg/kg/day (oral) 
al.,59 1983, U.K. (1) 
Sanders et al.,60 Posterior CsA 







Nussenblatt et aL6’ Behqeet’s CsA 10 mg/day (oral) 
1985, U.S.A. (n = 7) 
Wechsler et al.,@ 
1986, France 
BehGet’s CsA 10 mglkglday (oral) 




Remission in 1 week. CsA Renal dysfunction 
stopped after 10 days 
following elevation of 
creatinine. Within 7 days, 
creatinine back to normal. 
CsA restarted at 5 mg/kg/ 
day. Complete remission 
in 7 days. After 3 weeks, 
disease flared. CsA raised 
to 10 mglkglday with 
control of symptoms. 




CsA abrogated acute Gingivitis, 
phase of ocular attack. hypertrichosis, fatigue, 
Recurrences totally paresthesiae. renal 
prevented or markedly dysfunction 
reduced. Improvement 
also noted in nonocular 
complications of BehGet’s 
Suppression of disease, Hirsutism, gynecomastia 
hypertension, 
nephrotoxicity 
Mycosis Fungoldes (MF) 
Puttick et al.,63 Sezary 
1983. U.K. syndrome 
(1) 






CsA 17.5 mg/kg/day (oral) Within 1 week clearing of Renal and hepatic 
erythema and relief of dysfunction 
pruritus. Able to reduce 
dosage of prednisolone 
CsA 300 mg/day 
(intravenous route) 
initially. After 14 days 
changed to CsA 200 mg 
twice daily (oral) 
being taken concurrently 
Initial response in 10 days 
Improvement continued 
for first 12 weeks then 
deterioration 




TABLE 10-2. (Continued) 




patients Therapy Regimen Outcome 
Reported 
Side Effects 
Totterman et al.,65 Sezarv 
1985. Sweden 
Maddox et al.,66 
1985, U.S.A 
Jensen et a1.,67 
1987. Denmark 







CsA (oral) for 14 months 
CsA 5 mg/kg/day 
intravenous 
Patrent 1: Stage III MF CsA After a few days-marked 
12.4 mg/kg/day decrease in pruritus. Later 
(Intravenous). then dimunition in size of skin 
changed to oral CsA Then tumors. After 8 weeks drug 
disease flared discontinued 
Patient 1. Generalized 
erythroderma, inguinal 
lymphadenopathy CsA 5 
mg/kg/day. After 2 weeks, 
CsA increased to 7.5 mg/ 
kg/day 
After week l-complete Renal dysfunction 
resolution of pruritus. 
Marked decrease in 
erythroderma. After 7 
weeks, increased BUN and 
CsA decreased to 5 mg/ 
kg/day 
Pruritus responded 2-3 Renal dysfunction 
days. Decrease in 
erythema, number of 
tumor cells in skin and 
lymph nodes. Number of 
crrculating Sezary cells 
largely unaffected 
Within a few days, marked 
improvement in pruritus. 
Skin lesions improved. 
After 4 months, while still 
on CsA, pruritus and 
Infiltration recurred 
For other diseases see text 
this disease has generally not demonstrated 
significant response to CSA.‘~ 
Pyoderma gangrenosum has responded well 
to oral CsA therapy (6-10 mg/kg/day), with 
improvement occurring within 1.53 weeks of 
starting therapy.78-8” Oral CsA (7.5-9 mg/kg/ 
day) has also been reported to be of benefit 
in three patients with epidermolysis bullosa 
acquisita.*‘-a” A patient diagnosed as being a 
persistent light reactor demonstrated some 
improvement while on oral CsA (6 mg/kg/day); 
there was worsening of disease upon 
discontinuing CSA.~~ Picascia and Roenigk”” 
have reported one patient with male-pattern 
alopecia and psoriasis treated with oral CsA 
(7.5 mg/kg/day). Hair regrowth in areas of 
baldness was noticed while on CsA, with hair 
loss occurring upon discontinuation of CsA. In 
one case of cutaneous sarcoidosis, there was 
clearing of skin lesions within 2 weeks of 
starting oral CsA (10 mg/kg/day).8G Miller et 
al.*; reported the use of oral CsA in three 
patients with chronic, steroid-dependent 
erythema nodosum leprosum. Two patients 
demonstrated an excellent response, with a 
partial response in the third patient. 
Adverse Effects 
CsA has a spectrum of side-effects, many 
of which are dose dependent (Table 10-3). The 
following discussion focuses on the side effects 
that may occur during low-dose oral CsA in 
a nontransplant patient. The incidence of side 
effects can be minimized by careful patient 
selection, using the lowest CsA dose possible 
for short periods and monitoring blood trough 
levels of CsA. The triad of side effects that 
should be kept in mind is renal dysfunction, 
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TABLE 10-3. Side Effects of Oral Cyclosporine A 
Nephrotoxicity 
(see also electrolyte 
disturbances) 
*Elevation of serum BUN and creatinine 








Also see Cutaneous 
Noncutaneous: Non-Hodgkins lymphomas, lymphomas, others (see 
text) 
Benign tumors: benign breast tumors, papillary adenomas, fibroplasia of 
heart and kidneys 
Neurologic ‘Paresthesias, l dysesthesias, ‘hand tremors, muscle weakness, 
depression/psychosis, seizures, headache, encephalopathy 
Dental 
Gastrointestinal 
l Gingival hyperplasia 
*Nausea, ‘diarrhea/constipation 
Anorexia, indigestion, weight loss 





*Elevation of total and direct bilirubin 
Elevation of alkaline phosphatase 
Elevation of transaminases 
l Hypertrichosis 
Neoplasms-SCC, BCC, Kaposi’s sarcoma, others axillary hidradenitis, 
acne, folliculitus, skin thickening, epidermal cysts, sebaceous 
hyperplasia, breast tenderness, gynecomastia 
Musculoskeletal 
Hematologic 
*Fatigue, myalgias, joint pains 
Anemia, thrombocytopenia, elevation of ESR 
Leukopenia, erythremia, recurrent hemolytic uremic syndrome, 
increased risk for thromboembolic complications 
Infections Viral infections (eg, CMV, EBV, opportunistic infections such as 
pneumocystis pneumonia) 
Bacterial and fungal infections 
Miscellaneous *Flushing sensation, breast lumps, aseptic meningitis, myocardial 
infarction. anaina. fluid retention. visual imoairment. diabetes 
*Relatively common side effects that may occur in treatment of cutaneous diseases. 
Renal dysfunction is the most common side 
effect we have encountered and is dose-depend- 
ent. It is generally reversible upon lowering 
the dosage of CsA or upon discontinuing the 
drug. A dermatologist treating a patient with 
oral CsA in an outpatient setting can monitor 
for renal dysfunction by obtaining regular 
measurements of serum blood urea nitrogen, 
serum creatinine, creatinine clearance, CsA 
blood trough levels, and blood pressure. 
The use of CsA blood trough levels as a 
means of determining a safe therapeutic dose 
of CsA has not proved to be as successful as 
originally anticipated. There are multiple 
methods by which CsA blood levels can be 
measured. These include RIA, HPLC, and 
Clinics 
in 
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fluorescence polarization immunoassay 
(FPIA).88y89 The RIA method is a rapid and 
sensitive method for estimating the concentra- 
tion of CsA and its metabolites. Both monoc- 
lonal and polyclonal antibodies are available. 
Some can distinguish between the parent 
compound and metabolites. HPLC is more 
time consuming, but it can detect the parent 
drug and its metabolites separately with great 
precision. FPIA has been introduced recently 
to measure CsA blood levels; further details 
are given elsewhere.Rg Nonetheless, a rough 
correlation between CsA blood trough levels 
and nephrotoxicity exists. 
Two important points that need to be 
addressed are whether short-term, low-dose 
CsA can result in chronic renal dysfunction 
upon discontinuation of drug. To date this has 
not occurred in our experience. Whether long- 
term, low-dose oral CsA can lead to irreversible 
renal dysfunction still needs to be determined, 
but at low doses of CsA currently being used, 
available evidence suggests that this is 
unlikely. 
The development of hypertension is also dose 
dependent and is more likely to develop in 
patients with preexisting hypertension or 
renal dysfunction. In nontransplant patients 
receiving oral CsA, hypertension has been 
reported in approximately 25% patients.2”jX’ In 
our experience with low-dose, oral CsA (6 mg/ 
kg/day), if hypertension develops it is generally 
mild and can be controlled by dose reduction 
or discontinuation of CsA or by other standard 
medical measures. Blood pressure normalizes 
upon discontinuation of CsA. 
The majority of the information about the 
development of malignancy with CsA is avail- 
able at transplantation doses of CsA, usually 
when CsA has been used in conjunction with 
other immunosuppressive therapy. The inci- 
dence of lymphomas in patients treated with 
transplantation doses of CsA is similar to that 
seen with other immunosuppressive 
agents.gl-94 It is felt that in these transplant 
patients lymphomas develop as a result of their 
depth of immunosuppression rather than as 
a consequence of being on any particular 
immunosuppressive drug; long-term studies 
are needed to compare the effect of low-dose, 
single-agent CsA with conventional immuno- 
suppressive therapy. In otherwise healthy 
patients treated with low-dose oral Csh for a 
short period, the risk of lymphoma should be 
close to that of the general population. In view 
of the above, the lowest possible dose of CsA 
should be used. 
Other side effects that may be seen with oral 
CsA therapy are summarized in Table 10-3. 
Hypertrichosis is a common side-effect, occur- 
ring in 30-95% of transplant patients receiving 
CsA.““-gS With low-dose CsA, hypertrichosis 
was not found to be of clinical significance. 
Resolution normally occurs within l-2 months 
of discontinuing oral CsA. In a study per- 
formed by the present authors, gingival hyper- 
plasia occurred in 33% of 21 psoriatic patients 
who received oral CsA 14 mg/kg/day for 4 
weeks.2” The gingival changes were usually 
mild and resolved when CsA was discontinued. 
The clinical and histologic changes seen with 
gingival hyperplasia induced by CsA and phe- 
nytoin are essentially identica1.9*+‘9 Fatigue is 
a relatively common side effect, but it may 
improve with continued therapy. A flushing 
sensation, especially in the upper half of the 
body. may occur early in therapy; this also usu- 
ally subsides with continued therapy. 
Electrolyte abnormalities include hyper- 
kalemia, hypomagnesemia, and hyperurice- 
mia. Electrolytes should be monitored regu- 
larly, especially when patients have other 
medical problems. Transiently occurring 
gastrointestinal side-effects consisting of 
nausea, anorexia, upper abdominal discom- 
fort, and diarrhea are common, but these 
usually subside with continued therapy or 
upon lowering the dose of CsA. CsA metabol- 
ities are excreted mainly in the bile via the 
enterohepatic circulation. Excretion of CsA is 
reduced as a result of hepatic, pancreatic, or 
bowel dysfunction.100 In view of the above, 
patients with cutaneous disease who have sig- 
nificant preexisting hepatic dysfunction may 
not be suitable candidates for oral CsA ther- 
apy. With low-dose CsA, in otherwise healthy 
patients who have cutaneous disease, hepatic 
dysfunction consisting of elevated total and 
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direct bilirubin may occur but is usually mild, 
and it responds to lowering or discontinuing 
GSA. 
Neurologic side effects consisting of pares- 
thesias, dysesthesias, and hand tremors may 
be seen soon after starting CsA therapy and 
usually subside with continued therapy or 
following CsA dose reduction. Other less 
frequent neurologic side effects are given in 
Table 10-3. No increased risk of infection was 
seen with low-dose CsA given for short periods 
to otherwise healthy patients. This may be a 
serious side effect in already immunosup- 
pressed patients receiving higher doses of CsA. 
A mild normochromic, normocytic anemia has 
been reported with CsA therapy.‘O* We have 
not found this to be of clinical significance. 
Conclusions 
Oral CsA is an immunosuppressive agent 
that is increasingly being considered for treat- 
ment of various cutaneous conditions. The der- 
matoses most responsive to CsA appear to be 
psoriasis, Behcet’s disease, alopecia areata, 
psoriatic arthritis, pyoderma gangrenosum, 
and atopic dermatitis. Some other diseases 
such as pemphigus, bullous pemphigoid, 
dermatomyositis, and lupus erythematosus, 
have also demonstrated a response to therapy. 
The side effect profile of CsA may limit 
widespread use of this drug. Many of the side 
effects are dose dependent, and studies must 
be performed to determine the lowest effective 
dose in the CsA-responsive dermatoses. In any 
patient being considered for oral CsA, possible 
side effects should be weighed carefully 
against the benefits of therapy. 
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